EISAI CO., LTD. Unternehmen Eisai Co., Ltd. OTC Markets
Aktien
925692
US2825793092
ESALY
Pharmazeutika
Kurzporträt
- pharmazeutische Produkte (87,7%): verschreibungspflichtige Medikamente, Gesundheitsprodukte, etc;
- Sonstige (12,3%): Lebensmittelzusatzstoffe, chemische Produkte, usw.
Der Nettoumsatz verteilt sich geographisch wie folgt: Japan (46,2%), Europa (19,5%), Amerika (15,5%), China (10,3%) und Sonstige (8,4%).
Mitarbeiterzahl: 11 067
Umsatz nach Geschäftsbereich
| JPY in Millionen | 2023 | Gewichtung | 2024 | Gewichtung | Delta |
|---|---|---|---|---|---|
Pharmaceutical
93,2
%
| 684 434 | 91,9 % | 691 458 | 93,2 % | +1.03% |
Other
6,8
%
| 59 969 | 8,1 % | 50 293 | 6,8 % | -16.14% |
Umsatz je Region
| JPY in Millionen | 2023 | Gewichtung | 2024 | Gewichtung | Delta |
|---|---|---|---|---|---|
Americas
34,2
%
| 239 293 | 32,1 % | 253 756 | 34,2 % | +6.04% |
Japan
30,5
%
| 250 327 | 33,6 % | 226 445 | 30,5 % | -9.54% |
China
14,7
%
| 108 562 | 14,6 % | 109 283 | 14,7 % | +0.66% |
Europe
12,2
%
| 86 026 | 11,6 % | 90 528 | 12,2 % | +5.23% |
Other
8,3
%
| 60 195 | 8,1 % | 61 739 | 8,3 % | +2.56% |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01.10.75 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Keisuke Naito
COO | Chief Operating Officer | 35 | 01.10.13 |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Lynn Kramer
CTO | Chief Tech/Sci/R&D Officer | 73 | 01.07.09 |
Kenta Takahashi
BRD | Director/Board Member | 64 | 01.04.83 |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01.04.88 |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01.04.82 |
Masatomi Akana
IRC | Investor Relations Contact | 57 | 01.04.90 |
Sayoko Sasaki
IRO | Public Communications Contact | 55 | 01.04.91 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01.10.75 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 01.06.21 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Kenta Takahashi
BRD | Director/Board Member | 64 | 01.04.83 |
Ryota Miura
BRD | Director/Board Member | 50 | 01.06.21 |
Yuko Yasuda
BRD | Director/Board Member | 62 | - |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01.04.88 |
Yumiko Miwa
BRD | Director/Board Member | 58 | 01.06.20 |
| Director/Board Member | 59 | 17.06.22 | |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01.04.82 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 0 | 296 566 949 | 278 322 831 ( 93,85 %) | 9 531 401 ( 3,214 %) | 93,85 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
EISAI CO., LTD. 3,37% | 9 984 641 | 3,37% | 429 070 477 $ |
MATSUKIYOCOCOKARA & CO. 1,97% | 8 445 000 | 1,97% | 119 195 686 $ |
COGSTATE LIMITED 6,87% | 11 738 243 | 6,87% | 9 680 059 $ |
| 474 000 | 0,96% | 9 486 333 $ | |
ROIVANT SCIENCES LTD. 0,11% | 874 957 | 0,11% | 9 064 555 $ |
VITAL KSK HOLDINGS, INC. 1,24% | 642 154 | 1,24% | 5 541 128 $ |
| 349 000 | 0,43% | 3 202 508 $ | |
| 546 000 | 2,24% | 2 998 490 $ | |
| 56 608 | 0,14% | 173 990 $ | |
SUZUKEN CO., LTD. 0,00% | 100 | 0,00% | 3 020 $ |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Eisai Ltd. (United Kingdom)
 Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Ltd. is a British company that develops pharmaceutical products. The company is based in Hatfield, UK. The company was founded in 1988. Gary Bryan Hendler has been the CEO of the company since 2008. |
Pharmaceuticals: Major
|
Eisai Manufacturing Ltd.
 Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The company's official corporate website provides information on their initiatives and HHC concept. |
Pharmaceuticals: Major
|
Eisai Pharmaceuticals India Pvt Ltd.
 Eisai Pharmaceuticals India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Pharmaceuticals India Pvt Ltd. is an Indian company that manufactures and exports drug substances. The company is based in Visakhapatnam, India. The company was founded in 2007. The CEO is Sanjit Singh Lamba. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
| % 1. Jan. | Kap. | |
|---|---|---|
| +56.76% | 809 Mrd. | |
| +39.52% | 624 Mrd. | |
| -7.11% | 351 Mrd. | |
| +7.37% | 289 Mrd. | |
| +13.74% | 240 Mrd. | |
| +13.83% | 220 Mrd. | |
| -0.49% | 219 Mrd. | |
| +7.90% | 166 Mrd. | |
| -2.55% | 157 Mrd. |
